Enzyvant, a biotech that focuses on making regenerative medicines for rare diseases, is planning to build a new manufacturing facility in the Research Triangle Park Area of North Carolina.
The GMP-compliant regenerative medicine manufacturing facility is expected to span 25,972 square feet, according to a statement from Enyzvant. Construction will start this summer and should be finished by mid 2025. Enzyvant has not shared the financial details of the project yet.
The plant will mainly be used to make Rethymic, a medicine used to treat kids with congenital athymia, a rare autoimmune disorder where the body is born without a thymus. The thymus is an organ near the lungs that plays a big role in helping the body fight infections.
Going forward, Cambridge, Massachusetts-based Enzyvant wants to expand manufacturing at the new facility to other treatments and technologies, it said.
“This new facility, once completed, will give us the size, flexibility, and nimble processing capability to serve both commercial and research needs,” said William Symonds, CEO of Enzyvant.
Those research needs are in-part being served 20 mins down the road in nearby Durham, North Carolina, where Enzyvant currently has research and development offices.
“We’re excited that this new site not only expands the range and scope of our manufacturing offerings, but also builds our presence in Research Triangle Park – leveraging our existing employee base and [supporting] the local area with new hires,” said Larry Weiner, vice president of pharmaceutical development and manufacturing at Enzyvant.
The new facility will be co-developed by and operated with Sumitomo Pharma, which owns Sumitovant Biopharma, Enzyvant’s immediate parents.